Mochida Pharmaceutical Co., Ltd.

4534.T
Drug Manufacturers - Specialty & Generic
2026/04/06 Updated
Market Cap: $781.3M (¥124.6B)
Stock Price: $22.04 (¥3,515)
Exchange Rate: 1 USD = ¥159.49

Notice on Determination of Offering Price, etc.

Mochida Pharmaceutical Co., Ltd. has set the offering price for common shares at JPY 3,331 per share, with a total offering amount of approximately JPY 3,842.64 million, and an overallotment portion of 173,000 shares totaling approximately JPY 576.26 million. The application period is April 7 to 8, 2026, with the settlement date on April 13.

Importance:
Page Updated: April 6, 2026
IR Disclosure Date: April 6, 2026

Key Figures

  • Offering Price: JPY 3,331 per share
  • Total Offering Amount: JPY 3,842,641,600
  • Overallotment Offering Shares: 173,000 shares

AI要約

Summary of Capital Policy

Based on the resolution of the Board of Directors on March 30, 2026, Mochida Pharmaceutical Co., Ltd. has determined the offering price for common shares at JPY 3,331 per share. The offering will be conducted through an underwriting purchase method, with a total offering price amounting to approximately JPY 3,842.64 million. The underwriting price is JPY 3,193.60 per share, totaling approximately JPY 3,684.14 million. An overallotment offering of 173,000 shares totaling approximately JPY 576.26 million will also be implemented. The application period is from April 7 to April 8, 2026, with settlement scheduled for April 13. The offering price is set at a 3.03% discount against the reference price of JPY 3,435 as of April 6, 2026.

Impact on Shareholders and Future Schedule

This offering will increase the number of shares available in the market, potentially diluting existing shareholders; however, the exact increase rate in shares is not specified in the document. The exercise period for the green shoe option is from April 13 to April 23, 2026, and the syndicate cover transaction period is from April 9 to April 23, 2026. Additional offerings may be conducted during these periods. Investors are advised to carefully review the share offering prospectus before making decisions.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.